Skip to main navigation
  • Investors
    • Press Releases
    • Events
    • Stock Information
    • Financials
    • Governance
    • Investor Resources
    • Scientific Publications & Presentations
  • Newsroom
  • Medical Professionals
  • Careers
    • Intern Program
    • Postdoctoral Program
  • Contact Us
Ionis Pharmaceuticals, Inc. home page

Main navigation

  • About Us
    • Our Leadership
    • Our Culture
    • Corporate Responsibility
    • Grants & Sponsorships
  • Areas of Focus
  • Science & Innovation
    • Pipeline
    • Clinical Trials
    • Ion-ARPA Initiative
  • Medicines
  • Patients & Advocacy
    • Patient Stories
    • Patient Resources
    • Expanded Access Policy
Media Center

Investor Relations

  • Overview
  • Investor News
    • Press Releases
    • Company Statements
    • Media Kit
  • Events
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
    • Ownership Profile
  • Financials
    • SEC Filings
    • Annual Reports
  • Governance
    • Governance Documents
    • Committee Composition
  • Investor Resources
    • Investor FAQs
    • Settlement Information
    • Contact Us
  • Scientific Publications & Presentations
  • Investor Email Alerts

Investor contact

760-603-2331

Email

Media contact

760-603-4679

Email

Event Details

2025 American Academy of Allergy Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) Joint Congress

Feb 28 - Mar 3, 2025

Supporting Materials

Improvements in Quality-of-Life in Patients with HAE Receiving Donidalorsen 175 KB
Patient Preferences for Attributes of Prophylactic Treatment in Hereditary Angioedema A Discrete-Choice Experiment 700.1 KB
Participant-Reported Ease-of-Use With a Prefilled, Single-Dose, Disposable Autoinjector for the Treatment 406.7 KB
The Patient Experience Of Hereditary Angioedema Findings From A Racially Diverse Sample Of Adult Patients 282.2 KB
Patient-Reported Injection-Site Pain and Treatment Satisfaction After Switching From Long-Term Prophylaxis 503.2 KB
Hereditary Angioedema Disease Control After Switching to Donidalorsen From Prior Long-Term Prophylaxis 504.5 KB
Efficacy and Safety of Donidalorsen in Adolescent Patients With Hereditary Angioedema 324.8 KB
Correlation between Subjective and Objective Disease Control in Hereditary Angioedema Association between the Angioedema Control Test and Attack Rate 300.1 KB
Psychometric Validation of Angioedema Quality-Of-Life Questionnaire in Hereditary Angioedema Results from the OASIS-HAE Study 1.2 MB
Long-Term Analysis of the Phase 2 Open-Label Extension of Donidalorsen in Patients With Hereditary Angioedema 326.8 KB
Long-Term Prophylaxis for Hereditary Angioedema Real-World Treatment Patterns in Selected US Allergy Clinics 245.9 KB

Footer Navigation

  • Legal and Compliance:
    • Legal Notice
    • Code of Ethics and Business Conduct
    • Privacy Policy
    • Consumer Health Data Privacy Policy
    • Your Privacy Choices
    • Akcea Therapeutics
  • Information For:
    • Medical Professionals
    • Investors & Media
    • Job Seekers
    • Suppliers
  • Explore:
    • Our Story
    • Our Science
    • Our Pipeline
    • Our Culture
    • Our News
  • Stay Connected:
    • Contact Us
    • LinkedIn
    • X
    • Instagram
    • Facebook
    • Community Guidelines

©1989 – 2026 Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc.
Akcea Therapeutics® is a wholly owned subsidiary of Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc. logo